{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:30:48Z","timestamp":1768887048883,"version":"3.49.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.arcmed.2020.11.006","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T09:19:04Z","timestamp":1605604744000},"page":"261-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies"],"prefix":"10.1016","volume":"52","author":[{"given":"Gayathri","family":"Baburaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahadev","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2020.11.006_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(09)70069-5","article-title":"Nosocomial infections in patients with cancer","volume":"10","author":"Kamboj","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/SLA.0000000000001484","article-title":"Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways","volume":"264","author":"Longbottom","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.arcmed.2020.11.006_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib4","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.annonc.2020.04.002","article-title":"Testing for COVID-19 in lung cancer patients","volume":"31","author":"Passaro","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ntr\/ntaa059","article-title":"COVID-19 and smoking","author":"Berlin","year":"2020","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib7","author":"Yu"},{"key":"10.1016\/j.arcmed.2020.11.006_bib8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.annonc.2020.04.006","article-title":"Do Patients with Cancer Have a Poorer Prognosis of COVID-19? An Experience in New York City","volume":"31","author":"Miyashita","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3325\/cmj.2011.52.604","article-title":"Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study","volume":"52","author":"Miro\u0161evi\u0107 Skvrce","year":"2011","journal-title":"Croat Med J"},{"key":"10.1016\/j.arcmed.2020.11.006_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4103\/picr.PICR_132_16","article-title":"A study of harmful drug\u2013drug interactions due to polypharmacy in hospitalized patients in Goa Medical College","volume":"8","author":"Khandeparkar","year":"2017","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2020.11.006_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jsps.2013.01.001","article-title":"Emergency department visits and admissions due to drug related problems at Riyadh military hospital (RMH), Saudi Arabia","volume":"22","author":"Al-Arifi","year":"2014","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.arcmed.2020.11.006_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1586\/14737167.2013.851006","article-title":"Economic implications of potential drug\u2013drug interactions in chronic pain patients","volume":"13","author":"Taylor","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib14","doi-asserted-by":"crossref","first-page":"198070","DOI":"10.1016\/j.virusres.2020.198070","article-title":"COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking","volume":"286","author":"Magro","year":"2020","journal-title":"Virus Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12272-020-01258-7","article-title":"Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19","volume":"43","author":"Zou","year":"2020","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jmcb\/mjaa014","article-title":"Treating COVID-19 with Chloroquine","volume":"12","author":"Huang","year":"2020","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib17","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.11.006_bib18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2020.4742","article-title":"Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics","volume":"323","author":"Kalil","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2020.11.006_bib19","doi-asserted-by":"crossref","first-page":"106114","DOI":"10.1016\/j.ijantimicag.2020.106114","article-title":"Ribavirin therapy for severe COVID-19: a retrospective cohort study","volume":"56","author":"Tong","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2020.11.006_bib20","doi-asserted-by":"crossref","first-page":"112527","DOI":"10.1016\/j.ejmech.2020.112527","article-title":"A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir","volume":"201","author":"Liang","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.arcmed.2020.11.006_bib21","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2020.11.006_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib23","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","author":"Zhai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2020.11.006_bib24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.arcmed.2020.11.006_bib25","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib27","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.14309\/ajg.0000000000000832","article-title":"Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19","volume":"115","author":"Mather","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.05.034","article-title":"Covid-19 and lung cancer: A greater fatality rate?","volume":"146","author":"Jacobo","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.arcmed.2020.11.006_bib29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.annonc.2020.06.007","article-title":"COVID-19 in patients with lung cancer","volume":"31","author":"Luo","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib30","author":"IBM Micromedex\u00ae"},{"key":"10.1016\/j.arcmed.2020.11.006_bib31","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.arcmed.2020.11.006_bib33","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.arcmed.2020.11.006_bib38","first-page":"1","article-title":"The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications","volume":"4","author":"Khan","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.arcmed.2020.11.006_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225239","article-title":"Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases","volume":"14","author":"Suriyapakorn","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2020.11.006_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918818347","article-title":"Clinically relevant drug interactions with multikinase inhibitors: a review","volume":"11","author":"Hussaarts","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib42","first-page":"83","article-title":"The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects","volume":"45","author":"Bustos","year":"1994","journal-title":"Trop Med Parasitol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0976-500X.110892","article-title":"Assessment of proarrhythmic activity of chloroquine in in\u00a0vivo and ex\u00a0vivo rabbit models","volume":"4","author":"Khobragade","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.arcmed.2020.11.006_bib44","first-page":"e201834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib45","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(05)17950-1","article-title":"Blockade of HERG channels by HIV protease inhibitors","volume":"365","author":"Anson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2020.11.006_bib46","doi-asserted-by":"crossref","first-page":"1574806","DOI":"10.1155\/2018\/1574806","article-title":"Risk evaluation of Azithromycin-Induced QT prolongation in real-world practice","volume":"2018","author":"Choi","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.arcmed.2020.11.006_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.arcmed.2020.11.006_bib48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3332\/ecancer.2017.781","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014chloroquine and hydroxychloroquine as anti-cancer agents","volume":"11","author":"Verbaanderd","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.arcmed.2020.11.006_bib49","doi-asserted-by":"crossref","first-page":"102982","DOI":"10.1016\/j.critrevonc.2020.102982","article-title":"Considerations for interactions of drugs used for the treatment of COVID-19 with anti-Cancer treatments","author":"Jafari","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib50","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejphar.2009.06.063","article-title":"Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies","volume":"625","author":"Solomon","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib52","first-page":"ciaa237","article-title":"In\u00a0vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2020.11.006_bib53","doi-asserted-by":"crossref","first-page":"taz089","DOI":"10.1093\/jtm\/taz089","article-title":"Drug interactions with antimalarial medications in older travelers: a clinical guide","volume":"27","author":"Lewis","year":"2020","journal-title":"J Travel Med"},{"key":"10.1016\/j.arcmed.2020.11.006_bib54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/15563650500514558","article-title":"Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia","volume":"44","author":"Chen","year":"2006","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.arcmed.2020.11.006_bib55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/RHU.0b013e31829d5e50","article-title":"Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus","volume":"19","author":"Morgan","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib56","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.ijcard.2007.04.055","article-title":"Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine","volume":"127","author":"Stas","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib57","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)","volume":"95","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.arcmed.2020.11.006_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In\u00a0vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J Clin Virol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e328341dcc0","article-title":"Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations","volume":"25","author":"Soliman","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.arcmed.2020.11.006_bib60","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2020.11.006_bib61","first-page":"104","article-title":"Macrolides and torsadogenic risk: emerging issues from the FDA pharmacovigilance database","volume":"1","author":"Raschi","year":"2013","journal-title":"J Pharmacovigilance"},{"key":"10.1016\/j.arcmed.2020.11.006_bib62","doi-asserted-by":"crossref","first-page":"e0006034","DOI":"10.1371\/journal.pntd.0006034","article-title":"QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient","volume":"11","author":"Chinello","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.arcmed.2020.11.006_bib63","doi-asserted-by":"crossref","first-page":"866","DOI":"10.5414\/CP202388","article-title":"Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults","volume":"53","author":"Kumagai","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2020.11.006_bib65","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.amjcard.2004.02.025","article-title":"Famotidine and long QT syndrome","volume":"93","author":"Lee","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12012-014-9285-8","article-title":"Analysis of an ECG record database reveals QT interval prolongation potential of famotidine in a large Korean population","volume":"15","author":"Yun","year":"2015","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib67","first-page":"163","article-title":"Zykadia (Ceritinib) approved for patients with crizotinib-resistant ALK-positive non\u2013small-cell lung cancer","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.arcmed.2020.11.006_bib68","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.11.006_bib69","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.arcmed.2020.11.006_bib70","first-page":"83","article-title":"Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives","volume":"7","author":"Leprieur","year":"2016","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.arcmed.2020.11.006_bib71","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1753465816670498","article-title":"Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience","volume":"10","author":"Sullivan","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.arcmed.2020.11.006_bib72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2017.12.011","article-title":"Current perspective: osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring","volume":"91","author":"Schiefer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.arcmed.2020.11.006_bib73","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bcp.13488","article-title":"Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600\u2013mutant tumours","volume":"84","author":"Nebot","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib74","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.arcmed.2020.11.006_bib75","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s12325-013-0069-5","article-title":"Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies","volume":"30","author":"Grande","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.arcmed.2020.11.006_bib76","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12094-017-1706-2","article-title":"Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan","volume":"20","author":"Uhara","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib78","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1345\/aph.1Q422","article-title":"Protease inhibitor\u2013associated qt interval prolongation","volume":"45","author":"Hunt","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.arcmed.2020.11.006_bib79","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1161\/CIRCULATIONAHA.120.047521","article-title":"Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment","volume":"141","author":"Roden","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2020.11.006_bib80","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.2147\/OTT.S194870","article-title":"Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer","volume":"9","author":"Xu","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.arcmed.2020.11.006_bib81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-016-3087-6","article-title":"Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib","volume":"78","author":"Lam","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib82","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/FTD.0000000000000552","article-title":"Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients with Non-Small Cell Lung Cancer","volume":"40","author":"Ohgami","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.arcmed.2020.11.006_bib83","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1128\/AAC.00339-08","article-title":"Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax","volume":"53","author":"Lim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2020.11.006_bib84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib85","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF02976712","article-title":"Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes","volume":"26","author":"Kim","year":"2003","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib86","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/dmd.31.6.748","article-title":"In\u00a0vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation","volume":"31","author":"Projean","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.arcmed.2020.11.006_bib87","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","article-title":"Clinical pharmacokinetics and metabolism of chloroquine","volume":"31","author":"Ducharme","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.arcmed.2020.11.006_bib88","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/jps.22457","article-title":"An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in\u00a0vivo disposition of lopinavir and its modulation by ritonavir","volume":"100","author":"ter Heine","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.arcmed.2020.11.006_bib89","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1476-5381.2010.00759.x","article-title":"Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1\/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir","volume":"160","author":"Van Waterschoot","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib90","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/cpdd.723","article-title":"Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers","volume":"9","author":"Tugnait","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.arcmed.2020.11.006_bib91","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug\u2212 drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib92","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1590\/abd1806-4841.20153672","article-title":"New drugs, new challenges to dermatologists: mucocutaneous ulcers secondary to everolimus","volume":"90","author":"Pasin","year":"2015","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib93","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOT.0000000000000198","article-title":"New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease","volume":"20","author":"Kwo","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.arcmed.2020.11.006_bib94","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/QAD.0b013e328300ca98","article-title":"Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma","volume":"22","author":"Loulergue","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.arcmed.2020.11.006_bib95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2125.2009.03555.x","article-title":"Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients","volume":"69","author":"Mir","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib96","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00280-014-2399-7","article-title":"Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure","volume":"73","author":"Rudek","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib97","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fphar.2016.00071","article-title":"Drug\u2013drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection","volume":"7","author":"Berretta","year":"2016","journal-title":"Front. Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/molecules23020349","article-title":"Effects of phytochemical P-Glycoprotein modulators on the pharmacokinetics and tissue distribution of doxorubicin in mice","volume":"23","author":"Kim","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.arcmed.2020.11.006_bib99","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2147\/DDDT.S249098","article-title":"Pharmacokinetic-Based Drug\u2013Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review","volume":"14","author":"Zhao","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.arcmed.2020.11.006_bib100","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1124\/dmd.113.052100","article-title":"Ritonavir and efavirenz significantly alter the metabolism of erlotinib\u2014an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer","volume":"41","author":"Pillai","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.arcmed.2020.11.006_bib101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejpb.2019.01.016","article-title":"Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK\/ROS1 inhibitor lorlatinib","volume":"136","author":"Li","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.arcmed.2020.11.006_bib102","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/ijc.27912","article-title":"P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel","volume":"132","author":"Hendrikx","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2020.11.006_bib103","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.106.014407","article-title":"The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3","volume":"35","author":"Seithel","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.arcmed.2020.11.006_bib104","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2125.2000.00261.x","article-title":"Macrolide\u2013induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin","volume":"50","author":"Westphal","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00228-005-0091-x","article-title":"Quantitative prediction of macrolide drug-drug interaction potential from in\u00a0vitro studies using testosterone as the human cytochrome P4503A substrate","volume":"62","author":"Polasek","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib106","doi-asserted-by":"crossref","DOI":"10.1177\/1078155220931921","article-title":"Routine antiemetic prophylaxis with dexamethasone during COVID-19: Should oncologists reconsider?","author":"Marinella","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.arcmed.2020.11.006_bib107","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1046\/j.0014-2956.2001.02540.x","article-title":"Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes: sequential role of glucocorticoid receptor and pregnane X receptor","volume":"268","author":"Pascussi","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.arcmed.2020.11.006_bib108","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1067\/mcp.2000.110215","article-title":"In\u00a0vivo and in\u00a0vitro induction of human cytochrome P4503A4 by dexamethasone","volume":"68","author":"McCune","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2020.11.006_bib111","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biopha.2007.04.011","article-title":"Role of xenobiotic efflux transporters in resistance to vincristine","volume":"62","author":"Huang","year":"2008","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.arcmed.2020.11.006_bib112","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12815","article-title":"What do we know about remdesivir drug interactions?","author":"Yang","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.arcmed.2020.11.006_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","author":"Du","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2020.11.006_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib115","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: A Review in Rheumatoid Arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.arcmed.2020.11.006_bib116","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib117","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.arcmed.2020.11.006_bib119","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s00296-012-2423-3","article-title":"Interleukin-6 and cytochrome-P450, reason for concern?","volume":"32","author":"Kim","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.arcmed.2020.11.006_bib120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40261-013-0161-2","article-title":"Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir","volume":"34","author":"Wind","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.arcmed.2020.11.006_bib121","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bjc.6601236","article-title":"Supportive care in patients with advanced non-small-cell lung cancer","volume":"89","author":"Di Maio","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.arcmed.2020.11.006_bib122","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.arcmed.2020.11.006_bib123","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/bcp.13326","article-title":"QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings","volume":"83","author":"Isbister","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib124","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.yic.0000166405.49473.70","article-title":"Antipsychotic drugs and QT prolongation","volume":"20","author":"St\u00f6llberger","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/157488610789869256","article-title":"Other drugs acting on nervous system associated with QT-interval prolongation","volume":"5","author":"Keller","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.arcmed.2020.11.006_bib126","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/acem.12836","article-title":"Intravenous Ondansetron and the QT Interval in Adult Emergency Department Patients: An Observational Study","volume":"23","author":"Moffett","year":"2016","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.arcmed.2020.11.006_bib127","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2006.06.009","article-title":"Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine","volume":"544","author":"Kim","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7861\/clinmedicine.19-1-80","article-title":"Lesson of the month 1: Prolonged QT syndrome due to donepezil: a reversible cause of falls?","volume":"19","author":"Jackson","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.arcmed.2020.11.006_bib129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12020-017-1448-5","article-title":"Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies","volume":"60","author":"Pivonello","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2020.11.006_bib130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jfma.2018.01.016","article-title":"Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients","volume":"118","author":"Khan","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.arcmed.2020.11.006_bib131","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/JPR.S138698","article-title":"Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management","volume":"10","author":"Feng","year":"2017","journal-title":"J Pain Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib132","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/bja\/73.5.658","article-title":"Midazolam is metabolized by at least three different cytochrome P450 enzymes","volume":"73","author":"Wandel","year":"1994","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.arcmed.2020.11.006_bib133","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/psp4.12070","article-title":"Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling","volume":"5","author":"Zhou","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib134","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/jcph.1345","article-title":"Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors","volume":"59","author":"Sampson","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2020.11.006_bib135","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s12272-019-01201-5","article-title":"Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects","volume":"42","author":"Lee","year":"2019","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.arcmed.2020.11.006_bib136","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MAJ.0b013e31824ceb2b","article-title":"Ritonavir and epidural triamcinolone as a cause of iatrogenic Cushing's syndrome","volume":"344","author":"Albert","year":"2012","journal-title":"Am J Med Sci"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920311899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920311899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:49:26Z","timestamp":1759261766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440920311899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0188440920311899"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.11.006","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}